Leveraging biosimilars to drive savings and support patient access
By the end of 2024, 3 FDA-approved biosimilars to Stelara for patients living with inflammatory conditions will be closer to launch, enabling lower total drug spend.
Read More
The importance of a clinical-first approach to formulary development
The clinical efficacy of a drug must always take priority over any other considerations when developing formularies.
Read More
Here’s what drug makers don’t want you to know about PBMs
Pharmacy benefit managers shield patients from higher drug prices, but drug makers don’t want you to know that.
Read More
With the right formulary, plans can control drug costs while preserving access
Each plan determines which formulary is best for its unique circumstances.
Read More
Key considerations to support a robust biosimilar marketplace
We are taking a thoughtful and comprehensive approach to assessing biosimilar options that considers several factors.
Read More
Meet Mark Bini, Head of Growth and Coordinated Care for Evernorth Care Solutions
Mark Bini's love for numbers comes in handy in his role as the Head of Growth and Coordinated Care for Evernorth Care Solutions. Learn more about how Mark and his team take a data-driven approach to i...
Read More